Clinical Data

THOUSAND OAKS, Calif. – November 10, 2026 -- Amgen reported that an independent health economic analysis of its PCSK9 inhibitor Repatha (evolocumab) found the drug cost-effective at approximately 36% below the ACC/AHA benchmark in high-risk patients with no prior heart attack or stroke. The company presented the data at the American Heart Association (AHA) Scientific Sessions 2026.

Duke-led analysis uses patient-level VESALIUS-CV data

The Duke Clinical Research Institute led the study with the TIMI Study Group at Mass General Brigham and Harvard. It is the first independent health economic analysis built on individual-participant data from the Phase 3 VESALIUS-CV trial, and it compared treatment costs with projected health benefits. A separate analysis found that adding Repatha to standard therapy was highly cost-effective versus standard therapy alone in adults with atherosclerotic cardiovascular disease (ASCVD).

FOSTER CITY – November 10, 2026 -- OrthoTrophix reported that femoral bone shape stabilized in knees treated with its osteoarthritis candidate TPX-100, while it kept changing in placebo-treated knees, according to two posters presented at ACR Convergence 2026 in Orlando (November 6-11).

MRI analysis links B-score to meniscal pathology

Poster #1581, presented November 9, is a retrospective MRI analysis of a one-year, double-blind Phase 2a study of intra-articular TPX-100 in knee osteoarthritis (KOA). Femoral bone shape, measured by B-score, was significantly associated with baseline meniscal pathology at 6 and 12 months.

In placebo-treated knees, the bone-meniscus link strengthened over time. In TPX-100-treated knees, bone shape stabilized and the link weakened. The company says this suggests TPX-100 may alter the structural course of KOA in patients with high meniscal disease burden.

Boston – November 10, 2026 -- HotSpot Therapeutics reported preclinical data showing that its oral IRF5 inhibitor HST-2011 suppressed three disease-driving pathways in systemic lupus erythematosus (SLE) across human cell systems, human whole blood and cynomolgus monkeys. The data were presented in a poster at ACR Convergence 2026.

HST-2011 reduces B cell, interferon and cytokine readouts in three models

In human cellular systems, HST-2011 inhibited plasmablast formation and IgG production. It also potently inhibited type I interferon and proinflammatory cytokine production, including TNF and IL-1β.

In human whole blood stimulated with a TLR agonist, the compound reduced plasmablast, B-cell activation and interferon gene signature scores. mRNA sequencing showed reduced expression of IFNB1, TNF and IL1B.

Irvine, Calif. – November 08, 2026 -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), reported a statistically significant 42.4-point mean improvement in FACE-Q Satisfaction With Facial Appearance among 30 adults on GLP-1 medications who received combined neurotoxin and hyaluronic acid (HA) filler treatment. The result comes from HARMONY IN DIVERSITY, which the company describes as the first study of this combination in the GLP-1 population. Data from it and a second Phase 4 study, HALO, were presented at the American Society for Dermatologic Surgery (ASDS) Annual Meeting in San Diego, Nov. 5-8.

SHANGHAI – November 08, 2026 -- CureGene Pharmaceutical reported that its investigational P2Y12 antagonist Evategrel (CG-0255) produced comparable pharmacokinetics and platelet inhibition in Chinese and US healthy volunteers, clearing a key hurdle for running global trials in parallel. The data were presented as a poster at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago, held November 6-9.

Two clinical pharmacology studies test ethnic and food effects on oral Evategrel

One study compared oral Evategrel pharmacokinetics (PK) and pharmacodynamics (PD) in Chinese and US participants. The second examined how food affects exposure to the oral formulation and its antiplatelet effect. Both used the same design, with one run in the United States and one in China.

NEW BRUNSWICK, N.J. – November 07, 2026 -- Johnson & Johnson reported that 96% of Sjögren's disease patients interviewed after its Phase 2 DAHLIAS study cited mouth dryness as a symptom, making it both the most frequent complaint and the improvement patients prioritized most. The company will present the findings among 23 nipocalimab abstracts at the American College of Rheumatology (ACR) Convergence 2026.

Four core symptoms reported by more than 70% of interviewed patients

Besides mouth dryness (96%), patients most often reported fatigue (92%), eye dryness (90%) and joint pain (73%). Among women, 49% reported vaginal dryness. Patients said they saw improvements across many of these symptoms during the treatment phase.

Sjögren's disease is a chronic, systemic, autoantibody-driven condition affecting approximately four million people worldwide. It is nine times more common in women than in men.

Boston – November 06, 2026 -- Servier will present nine abstracts, including five oral presentations, at the 31st Society for Neuro-Oncology (SNO) Annual Meeting, held November 12-15 in Philadelphia. The package covers both of its glioma therapies: VORANIGO (vorasidenib) in IDH-mutant glioma and OJEMDA (tovorafenib) in BRAF-altered pediatric low-grade glioma (pLGG).

Four-year FIREFLY-1 data to cover retreatment after progression in pLGG

One oral presentation will deliver updated results from the four-year follow-up of the Phase 2 FIREFLY-1 study of OJEMDA in relapsed or refractory BRAF-altered pLGG. The analysis includes data on post-treatment observation and on retreatment with OJEMDA after disease progression.

SAN FRANCISCO – November 06, 2026 -- AusperBio's investigational antisense oligonucleotide AHB-137 maintained functional cure in 16 of 17 evaluable nucleos(t)ide analogue (NA)-treated chronic hepatitis B participants 12 months after they stopped all HBV treatment, according to long-term follow-up data from Study AB-10-8004. No participant required NA re-initiation during follow-up.

Nine of nine evaluable NA-treated participants stay cured at 15 months

In the NA-treated cohort, functional cure held in 9 of 9 evaluable participants at 15 months after NA discontinuation. The cohort enrolled 34 participants (21 complete responders, 13 partial responders) from the Phase 2 studies AB-10-8002 and AB-10-8003.

Shanghai – November 05, 2026 -- Dizal (SSE: 688192) will present three oral and five poster presentations from its hematological disease portfolio at the 68th American Society of Hematology (ASH) Annual Meeting, including the first clinical data for its EZH1/2 inhibitor GW5282 in relapsed or refractory non-Hodgkin lymphoma (r/r NHL).

Golidocitinib data extend from lymphoma into secondary HLH

An oral presentation will report updated results for golidocitinib monotherapy in adults with secondary hemophagocytic lymphohistiocytosis (HLH). The data extend findings shown at the European Hematology Association (EHA) Congress 2026. Dizal reports high and durable response rates with a manageable safety profile, which it says supports further development in the indication.

Gothenburg – November 04, 2026 -- Radiotherapy is applied in as few as 12–22% of radically treated prostate cancer patients in some European national registries, even though nearly all men with non-metastatic disease requiring active treatment are candidates for it under European Association of Urology (EAU) guidelines. Clinicians and Swedish medtech firm Micropos Medical are now pushing to raise awareness of high-precision radiotherapy as an alternative to surgery.